NBTXR3
Phase 1/2Recruiting 2 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Locally-Advanced Non-Small Cell Lung Cancer
Conditions
Locally-Advanced Non-Small Cell Lung Cancer
Trial Timeline
Apr 30, 2026 → Aug 30, 2030
NCT ID
NCT07224152About NBTXR3
NBTXR3 is a phase 1/2 stage product being developed by Nanobiotix for Locally-Advanced Non-Small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07224152. Target conditions include Locally-Advanced Non-Small Cell Lung Cancer.
Hype Score Breakdown
Clinical
9
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07224152 | Phase 1/2 | Recruiting |
Competing Products
1 competing product in Locally-Advanced Non-Small Cell Lung Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BYL719 + Letrozole + Exemestane | Novartis | Phase 1 | 29 |